EXTRA-A Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 1, 2008, Pages 119-126

  Glynne Jones, Rob ^a   Meadows, Helen ^b,c   Wan, Susan ^b,c   Gollins, Simon ^d   Leslie, Martin ^e   Levine, Ed ^f   McDonald, Alec C ^g   Myint, Sun ^h   Samuel, Les ⁱ   Sebag Montefiore, David ^j  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GLAN CLWYD HOSPITAL   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

ⁱ ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^j Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

more..

Author keywords

Anal cancer; Capecitabine; Mitomycin C; Radical chemoradiation

Indexed keywords

ELECTROTHERAPEUTICS; RADIOTHERAPY; STANDARDS;

5-FLUOROURACIL; ANAL CANCER; CAPECITABINE; CHEMORADIATION; CHEMORADIOTHERAPY; CLINICAL TRIALS; MITOMYCIN C; PHASE II; RADICAL CHEMORADIATION;

METALLIC MATRIX COMPOSITES;

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; CAPECITABINE; CIPROFLOXACIN; FLUCONAZOLE; FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ALOPECIA; ANOREXIA; ANUS CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; DYSURIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INGUINAL REGION; LETHARGY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PALMAR PLANTAR SYNDROME; PATIENT COMPLIANCE; PERINEUM; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; SCROTUM; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; STOMATITIS; TENESMUS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY FREQUENCY; VOMITING; WOUND DRESSING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GREAT BRITAIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; RADIOTHERAPY DOSAGE; REMISSION INDUCTION;

EID: 49549091339     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.12.012     Document Type: Article

References (23)

1. Marti M.C., and Givel J.C. Malignant anal tumours in surgical management of anorectal disease (1987), Springer-Verlag, Berlin
2. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin c. Lancet 348 (1996) 1049-1054
3. Bartelink H., Roelofson F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a Phase III randomized trial of the European Organisation for Research and Treatment of Cancer radiotherapy and gastrointestinal groups. J Clin Oncol 15 (1997) 2040-2049
4. Flam M., John M., Pajak T.F., et al. Role of mitomycin in combination with fluorouracil and radiation, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomised intergroup study. J Clin Oncol 14 (1996) 2527-2539
5. Schuller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumour following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 45 (2000) 291-297
6. Cunningham D., Rao S., Starling N., et al. Randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. [abstract]. J Clin Oncol 24 18S (2006) 4017
7. Cassidy J., Scheithauer W., McKendrick J., et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a Phase III trial. J Clin Oncol 22 Suppl. 14S (2004) 3509
8. Twelves C., Boyer M., Findlay M., et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a Phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37 (2001) 597-604
9. National Institute of Health. NCI: Common Toxicity Criteria, Version 2.0. Available at http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf. Accessed October 22, 2007.
10. Fleming T.R. One-sample multiple testing procedure for Phase II clinical trials. Biometrics 38 1 (1982) 143-151
11. Sladowski K., Law M.G., Maciejewski B., et al. Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiother Oncol 30 (1994) 109-120
12. Ajani J.A., Winter K.A., Gunderson L.L., et al. Intergroup RTOG 98-11: a Phase III randomized study of 5-fluorouracil, cisplatin, and radiotherapy in carcinoma of the anal canal. [abstract]. J Clin Oncol 24 Suppl. 18 (2006) 4009
13. Bosset J.F., Roelofsen F., Morgan D., et al. Radiochemotherapy in locally advanced anal carcinoma (LAAC). Results of the 22953 EORTC Phase II trial. [abstract]. Eur J Cancer 37 Suppl. 6 (2001) 84
14. Kovach J.S., and Beart Jr. R.W. Cellular pharmacology of fluronated pyrimidines in vivo in man. Invest New Drugs 7 (1989) 13-25
15. Van Cutsem E., Hoff P.M., Harper P., et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, Phase III trials. Br J Cancer 90 (2004) 1190-1197
16. Twelves C., Wong A., Nowacki M., et al. Capecitabine as adjuvant therapy for Stage III colon cancer. New Engl J Med 352 (2005) 2696-2704
17. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20 (2002) 3983-3991
18. Ngan S., Michael M., Mackay J., et al. A Phase I study of preoperative and capecitabine for locally advanced potentially resectable rectal cancer. Br J Cancer 91 (2004) 1019-1024
19. Mawdsley S. The role of biological molecular markers in predicting both response to treatment and clinical outcome in squamous cell carcinoma of the anus [abstract]. Published proceedings GI ASCO 2004. GI American Society of Clinical Oncology (2004) 183
20. Sawada N., Ishikawa T., Sekiguchi F., et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine in human cancer xenografts. Clin Cancer Res 5 (1999) 2948-2953
21. James R., and Meadows H.M. The second UK Phase III anal cancer trial of chemoradiation and maintenance therapy (ACT II): preliminary results on toxicity and outcome. [abstract]. Proc Am Soc Clin Oncol 22 (2003) 1151
22. Gerard J.P., Chapet O., Samiei F., et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal. Experience in a series of 270 patients treated in Lyon and review of the literature. Cancer 92 (2001) 77-84
23. Cummings B.J., and Brierley J.D. Anal canal. In: Perez C.A., Brady L.W., Halperin E.C., et al. (Eds). Principles and practice of radiation oncology. 4th ed. (2003), Williams and Wilkins, Philadelphia 1630-1648